



Axxam expands its integrated HTS platforms through the acquisition of Hit Discovery Constance GmbH

May 27th, 2021 - Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”).

In 2014 Hit Discovery Constance GmbH (HDC, www.hit-discovery.com) was founded as a joint venture company between Axxam SpA (Milan, Italy), Centre for Drug Design and Discovery of KU Leuven (Leuven, Belgium) and Lead Discovery Center GmbH (Dortmund, Germany). Under the leadership of Dr. Thilo Enderle, HDC became a qualified provider of early-stage drug discovery services for the life sciences industry. The high-quality services offered include: high-throughput screening (1536 and 384 well formats), high-content and radiometric screening (SPA, flash-plate), as well as compound storage and management services (acoustic dispensing – 1536 format).

The acquisition of HDC by Axxam responds to the increasing requests from the market for capacity and capabilities in the HTS arena including also compound logistics. HDC will enhance the Axxam Group’s portfolio of services offered in the HTS field with complementary technological platforms and additional scientific expertise, expanding the capacity of laboratory space and qualified personnel to meet the needs of our clients.

Stefan Lohmer, Chief Executive Officer at Axxam said: “We are all extremely pleased to welcome HDC into the Axxam Group and we are strongly committed to position HDC towards a relevant screening hub based in the middle of Europe, serving both academic and industrial clients. Konstanz is a very attractive location (DACH region) which has access to a great talent pool and offers an attractive environment for life science-based companies”.

Thilo Enderle, Managing Director at HDC said: “We are all excited about this transaction from which HDC will gain sustainability and stable progress into the future, now being part of one of the largest *in-vitro* research biology company worldwide with 20 years of successful drug discovery experience. It will permit HDC to further invest in people and infrastructure, to integrate our technologies even more closely and to foster the business of the Axxam Group, resulting in a significant growth”.

About Axxam SpA

Axxam SpA is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industry including pharmaceutical, crop protection, animal health, cosmetics and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS and HCS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. For more information, please visit www.axxam.com.